Tulane Urology boasts over 3300 square feet of research laboratory space. This space includes a basic research area and Tulane Urology has state-of-the-art equipment, such as its own molecular biology laboratory (with equipment). There is also a specific clinical research office and though research is not mandated every effort is made to provide residents with necessary tools to fulfill any desire that the residents may have to embark on research and hopefully an academic career. Dr. Asim Mageed and Surresh Sikka head our extensive basic research facility.
Oliver Sartor, MD
Dr. Sartor has been involved in a leadership role with a Phase III trial prolonging survival in advanced prostate cancer. Given that there are only five trials in history to obtain this feat, the fact that Dr. Sartor has been involved in two out of the five in a leadership role has been notable.
The first trial involved second-line chemotherapy with Cabazitaxel and this trial has now been published in Lancet as well as gaining FDA approval in June 2010. It is the first trial to demonstrate a survival benefit after initial chemotherapy had failed. Dr. Sartor was the international co-principal investigator for this trial, and senior author on the Lancet paper.
In the new trial, recently announced, the use of the new isotope Radium 223 has resulted in a prolong survival of a polaroid of patients with advanced metastatic prostate cancer and this is the first radio-pharmaceutical to prolong life in prostate cancer and in all likelihood will result in a FDA approval. Dr. Sartor was the North American principal-investigator in this trial.
Dr. Sartor was a local investigator (but without a national leadership role) in a third trial which led to a prolongation in survival in metastatic prostate cancer using Abiraterone. He currently is involved with his fourth Abiraterone study here at Tulane which is the first second-line hormonal agent to demonstrate survival benefits. Abiraterone is now FDA approved.
He currently runs approximately ten clinical trials in prostate cancer and is a national co-principal investigator in three of these trials.
Asim Abdel-Mageed, PhD
Active Research Projects
"Targeting Tumor-Derived exRNA-Containing Microvesicles by High Throughput Screening"
"Estrogen-ER Axis in Disparity of Prostate Cancer"
"Adipose stem cell-based therapeutic targeting of residual androgens in African Americans with bone metastatic prostate cancer" Co-Invest: Raju Thomas, K. Moparty
Dr. Abdel-Mageed's laboratory primarily focuses on basic research into the cellular and molecular aspects of urologic diseases, with particular attention given to prostate and bladder cancer. The laboratory has a special interest in identifying molecular determinants of prostate cancer progression using in vitro and in vivo experimental approaches.
Suresh Sikka, PhD
Men's Health (Male Infertility, Sexual Dysfunction, Genitourinary Inflammation, Prostate Diseases, Environmental Reproductive Toxicology, Role of Oxidative Stress/Antioxidants, Sperm Safety Multicenter Clinical Studies, Forensic Applications, Endocrine Disruptors, and Andropause)